Georgia's Online Cancer Information Center

Find A Treatment Site

Northside Hospital Cancer Institute

Northside Hospital Cancer Institute
Atlanta, Georgia

Northside Hospital Cancer Institute offers the best of both worlds: clinical excellence on par with academic-based programs, along with the personalized and attentive care typically associated with a community hospital. Northside, which has been offering cancer care services since 1978, is one of the largest and most respected providers of cancer care services in the Southeast.


  • The Blood & Marrow Transplant Program at Northside Hospital has ranked #1 in the United States for the third consecutive year, for having the best survival rates for matched related and unrelated donors (MUD) /allogeneic transplants.
  • More cases of breast cancer and gynecologic (cervical, ovarian and uterine) cancer are diagnosed and treated than at any other hospital in the Southeast.
  • More prostate cancer treatments are performed at Northside than at any other hospital in Atlanta
  • Fully accredited by the American College of Surgeons Commission on Cancer.
    Northside also received an Outstanding Achievement Award.

Our renowned program also consists of palliative care, cancer genetics, screenings, research, support and survivorship.

(404) 851-8000
www.northside.com

Treatment Sites in Georgia

Clinical Trials in Georgia

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Cancer Type: Unspecified

A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).
Cancer Type: Lymphoma
Study Coordinator: Stacey Brown - 404-780-7965


A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Cancer Type: Multiple Primaries
Study Coordinator: Stacey Brown - 404-780-7965


A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3 / ITD AML
Cancer Type: Unspecified
Study Coordinator: Stacey Brown - 404-780-7965


A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type: Head and Neck Cancer, Lung Cancer
Study Coordinator: Anila Lokhandwala - 404-256-4777 x9242


A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome / Acute Myeloid Leukemia
Cancer Type: Myelodysplastic Syndromes (MDS)

A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Cancer Type: Lymphoma, Myelodysplastic Syndromes (MDS)
Study Coordinator: Stacey Brown - 404-780-7965


A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R / R) B-cell Non-Hodgkin Lymphoma (NHL)
Cancer Type: Lymphoma, Non-Hodgkin Lymphoma
Study Coordinator: Stacey Brown - 404-780-7965


A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type: Unknown Primary
Study Coordinator: Anila Lokhandwala - 404-256-4777 x9242


A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary
Study Coordinator: - 404-303-3355


A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Cancer Type: Colon/Rectal Cancer
Study Coordinator: Anila Lokhandwala - 404-256-4777 x9242


A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Cancer Type: Lymphoma, Multiple Myeloma
Study Coordinator: Stacey Brown - 404-780-7965


A Phase I / II Study of SEL24 in Patients With Acute Myeloid Leukemia
Cancer Type: Unspecified
Study Coordinator: Stacey Brown - 404-780-7965


A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
Cancer Type: Breast Cancer, Unknown Primary

A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


A Phase II Study of Rucaparib in Patients with Genomic LOH High and / or Deleterious BRCA1 / 2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Cancer Type: Unspecified

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I / II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4 / RTOG-3515)
Cancer Type: Lung Cancer

A Randomized Double-blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Cancer Type: Non-Hodgkin Lymphoma
Study Coordinator: Stacey Brown - 404-780-7965


A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Cancer Type: Ovarian Cancer

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355


A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients with Residual Triple-Negative Basal-like Breast Cancer following Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355


A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355


A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type: Melanoma, Unknown Primary
Study Coordinator: - 404-303-3355


A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary
Study Coordinator: - 404-303-3355


A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355


A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Cancer Type: Unspecified

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Cancer Type: Melanoma, Skin Cancer (Non-Melanoma)
Study Coordinator: - 404-303-3355


ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Cancer Type: Ovarian Cancer
Study Coordinator: Jen Cuvo - 404-236-8304


Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Cancer Type: Brain Cancer
Study Coordinator: - 404-303-3355


EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
Study Coordinator: - 404-303-3355


INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction / Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens
Cancer Type: Breast Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation
Cancer Type: Bladder Cancer
Study Coordinator: - 404-303-3355


Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Cancer Type: Brain Cancer
Study Coordinator: - 404-303-3355


Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Breast Cancer, Unknown Primary
Study Coordinator: - 404-303-3355


Protocol For A Research Database For Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries
Cancer Type: Hematologic Malignancies
Study Coordinator: Stacey Brown - 404-780-7965


Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Cancer Type: Lung Cancer
Study Coordinator: Renee Gaiter - 404-303-3355


Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355


Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease
Cancer Type: Unspecified
Study Coordinator: Stacey Brown - 404-780-7965


The National Myelodysplastic Syndromes (MDS) Study
Cancer Type: Myelodysplastic Syndromes (MDS)
Study Coordinator: - 404-303-3355


Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Cancer Type: Unspecified
Study Coordinator: - 404-303-3355
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.